Parallel Advisors LLC Increases Holdings in Novo Nordisk A/S $NVO

Posted by Geri Gentry on Aug 7th, 2026

Parallel Advisors LLC raised its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 27.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 55,856 shares of the company’s stock after purchasing an additional 12,138 shares during the quarter. Parallel Advisors LLC’s holdings in Novo Nordisk A/S were worth $2,053,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Godfrey Financial Associates Inc. purchased a new position in Novo Nordisk A/S in the 4th quarter worth approximately $25,000. WealthCollab LLC lifted its position in shares of Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after purchasing an additional 260 shares in the last quarter. Jackson Grant Investment Advisers Inc. purchased a new position in shares of Novo Nordisk A/S in the fourth quarter valued at $29,000. Maseco LLP acquired a new stake in Novo Nordisk A/S during the 4th quarter valued at $29,000. Finally, Transamerica Financial Advisors LLC increased its stake in Novo Nordisk A/S by 201.5% during the 4th quarter. Transamerica Financial Advisors LLC now owns 603 shares of the company’s stock worth $31,000 after buying an additional 403 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on NVO. BMO Capital Markets restated a “market perform” rating and set a $47.00 target price on shares of Novo Nordisk A/S in a research note on Thursday. Wall Street Zen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Zacks Research lowered Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. Finally, Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday. Five investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $65.81.

Get Our Latest Stock Analysis on NVO

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

Positive Sentiment: Strong quarterly results and raised outlook: Novo Nordisk beat second-quarter revenue expectations by approximately 10% and adjusted EPS estimates by more than 20%. Revenue increased 7% year over year, operating profit rose 11%, and management lifted its 2026 sales and profit outlook for the second time this year. Novo Nordisk: The Market Has Lost Its Mind, Too Cheap To Ignore
Positive Sentiment: Continued GLP-1 demand: International markets and obesity care continued to drive growth, while accelerating demand for the Wegovy pill supported the improved outlook. The company also retains substantial profitability and cash generation to fund research, development and shareholder returns. NVO Q2 Earnings Call Centers on Wegovy Pill and Outlook Lift
Positive Sentiment: Patent enforcement win: A Dutch court ordered Ceban Ziekenhuisfarmacie to stop selling an infringing compounded semaglutide nasal spray, remove product listings and provide supply-chain information. The ruling could help protect Novo’s semaglutide franchise from unauthorized competition in the Netherlands. Novo Nordisk wins Dutch court injunction
Neutral Sentiment: Novo declared a dividend of 0.5786 per share, payable August 25 to shareholders of record August 17. The reported 254% yield appears inconsistent with the stated dividend and should be treated cautiously pending confirmation. Novo Nordisk dividend and insider transactions announcement
Negative Sentiment: Pipeline and competitive concerns remain the main overhang: Investors focused on weaker-than-expected Wegovy pill sales, a setback for the next-generation obesity treatment CagriSema, U.S. pricing pressure and the widening commercial lead of Eli Lilly’s GLP-1 portfolio. These issues overshadowed the earnings beat and guidance increase. The divide between Eli Lilly and Novo Nordisk is widening

Novo Nordisk A/S Price Performance

Shares of NVO opened at $45.90 on Friday. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $64.16. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The firm has a market cap of $204.96 billion, a price-to-earnings ratio of 11.22, a PEG ratio of 4.06 and a beta of 0.76. The stock has a 50 day moving average of $46.96 and a 200-day moving average of $45.01.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The business had revenue of $11.98 billion for the quarter. As a group, analysts forecast that Novo Nordisk A/S will post 3.39 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a dividend, which will be paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th will be issued a dividend of $0.5786 per share. This represents a dividend yield of 254.0%. The ex-dividend date of this dividend is Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio is 42.79%.

About Novo Nordisk A/S

(Free Report)

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.